Apillet participated in the 14th International Conference and Exhibition on Nutraceuticals and Functional Foods – October 02 – 05, 2022 – Istanbul
Roskilde October 5, 2022
CEO Anders Christesen presented the talk
“The development of an enteric capsule made from natural materials for oral delivery of Probiotics / Nutraceuticals”
at the 14th International Conference and Exhibition on Nutraceuticals and Functional Foods – October 02 – 05, 2022 – Istanbul.
Apillet ApS Announces in-vitro testing of APIVault tablet Prototype.
Company announcement No. 01/2022
Apillet ApS Announces the in-vitro testing of APIVault tablet Prototype.
Apillet ApS, a Danish biotech company, develops gastro resistant enteric encapsulations for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals, today announces the first prototype of the APIVault enteric technology for targeted delivery in the small intestine and the colon.
The APIVault encapsulation material is produced solely from natural materials with a combination of bacterial cellulose and cellulases as basis. The prototype is a tablet protecting the enclosed substance against enzymatic degradation and low pH in the stomach. The tablets can be programmed to release the substance at a predetermined location in the small intestine or in the colon.
Apillet has through recent development work obtained further knowledge of the protection properties, release properties and design parameters of APIVault. A formula for targeted release at locations in the small intestine and the colon has been designed. Furthermore, prototypes have been produced.
We are now testing the release properties of a model substance to further validate the APIVault. We are looking for first candidate Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics or Nutraceuticals to test release properties in-vitro and in-vivo.
About APILLET ApS
Apillet ApS, (CVR-no. 41388285) is a biotech company based in Roskilde Denmark, that develops gastro resistant enteric encapsulations for oral delivery of Biopharmaceuticals, Sensitive pharmaceuticals, Probiotics and Nutraceuticals.
The encapsulation retains the payload until a well-defined percentage of the BC membrane has been digested by the cellulase. When this digestion threshold has been reached there is a sudden change in permeability and the payload is fully released over a short span of time. This release pattern can be explained by a phenomenon known in materials science as percolation. New in vitro data defines narrow boundaries on the percolation threshold of the BC membrane.
The release pattern provides excellent opportunities for controlling the entestinal site of release together with opportunities for controlling the time window for release.
This substantiates that the ApiVault Technology can deliver targeted release of probiotics, prebiotics, nutraceuticals, enzymes, biologics, peptides and small molecules in predestined segments of the intestine.
Apillet to participate in BIOTECHGATE DIGITAL PARTNERING:
Roskilde April 15. 2021
Apillet will attend the international partnering-event BIOTECHGATE DIGITAL PARTNERING May 3 – 7, 2021 that gathers decision-makers from the industry. We are looking for an investor / financing, for clients and partners and for R&D collaborations and partnerships. Please get in touch if you would like to schedule a meeting with Apillet.
Apillet enters into collaboration with BCTechnology:
Roskilde April 1. 2021
Apillet announces the start of a new collaboration with BCTechnology, Braga Portugal on the the development of a protoptype and an industrial master formula for APIVAULT, Apillets novel gastro-resistant enteric encapsulation technology.
We are very happy to have signed a contract with BCTechnology on the development of APIVAULT in the laboratory of BCTechnology. BCTechnology is home to world leading expertease in bacterial cellulose and cellulases. It is the ideal collaborator on the development journey of APIVAULT into the pre-clinical phase.
Apillet receives angel investment:
Roskilde March 20. 2021
Apillet ApS has secured the financing of the prototype and industrial master formula development of APIVAULT, Apillets novel gastro-resistant enteric encapsulation technology. The project paves the way to preclinical testing of the APIVAULT technology.
The financing is in the form of an angel investment. Apillet is actively looking for additional investments or pharma collaboration for funding the preclinical and clinical development of APIVAULT.
Apillet receives investment from Innovation Fund Denmark:
Roskilde, Denmark, December 21 2020
Apillet has secured soft funding through an Innobooster investment from Innovation Fund Denmark.
This enables initiation of key activities with international partners, including development of a prototype of and an industrial master formula for APIVAULT, Apillets novel gastro resistent enteric encapsulation Technology.
The Apillet team is grateful to Innovation Fund Denmark for the recognition.
7 – 10 December, 2020 Apillet was represented by CEO Anders Christensen and strategic advisor Michael Plougmann at the BioFit virtual partnering conference . Apillet was invited to participate in a business pitch session. The pitch was given on the 7th of December the first day of the conference. The pitch presented both the technical aspects, business aspects and project plans for the company. The pitch is in this YouTube link (starts at 38:00) or you can find it below. Over 10 selected collaboration meetings were held during the conference. Thank you for all the important conversations and possibilities that resulted from this event.
23 – 26 November, 2020 CEO Anders Christensen and strategic advisor Michael Plougmann represented Apillet in the Biotechgate Digital Partnering virtual business development event. More than 10 selected partnering meetings were conducted. Thank you for all the valuable discussions and opportunities that emerged from this event.
5th November, 2020 Apillet participated in the Developments and Innovations in the Drug Delivery Market meeting.
Thank you so much for the conversations that resulted from this event.